IRIS
FALASCA, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.219
EU - Europa 3.657
AS - Asia 2.312
SA - Sud America 262
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 10.467
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.171
SG - Singapore 905
CN - Cina 712
IT - Italia 707
IE - Irlanda 674
SE - Svezia 515
UA - Ucraina 510
TR - Turchia 353
GB - Regno Unito 303
DE - Germania 279
BR - Brasile 247
FR - Francia 224
FI - Finlandia 172
IN - India 138
RU - Federazione Russa 114
KR - Corea 86
AT - Austria 37
HK - Hong Kong 36
VN - Vietnam 33
CA - Canada 29
NL - Olanda 27
BE - Belgio 18
CZ - Repubblica Ceca 17
RO - Romania 13
MX - Messico 9
BD - Bangladesh 8
CH - Svizzera 8
ES - Italia 7
EC - Ecuador 6
AR - Argentina 5
LT - Lituania 5
PL - Polonia 5
TW - Taiwan 5
AZ - Azerbaigian 4
EU - Europa 4
HR - Croazia 4
IL - Israele 4
IQ - Iraq 4
EE - Estonia 3
JP - Giappone 3
AU - Australia 2
BB - Barbados 2
BG - Bulgaria 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
ID - Indonesia 2
IR - Iran 2
KE - Kenya 2
LV - Lettonia 2
MA - Marocco 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
VE - Venezuela 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
CY - Cipro 1
EG - Egitto 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
ME - Montenegro 1
MK - Macedonia 1
MM - Myanmar 1
MY - Malesia 1
NI - Nicaragua 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
SN - Senegal 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.467
Salva come PNG Salva come JPEG
Città #
Chandler 780
Jacksonville 696
Dublin 657
Singapore 615
Princeton 318
Southend 244
Nanjing 215
Izmir 195
Ashburn 177
The Dalles 166
Altamura 141
Santa Clara 135
Chieti 111
Dearborn 108
Beijing 105
Wilmington 104
Cambridge 97
Ann Arbor 87
Boardman 74
Nanchang 65
Munich 60
Pescara 56
Los Angeles 51
Helsinki 43
New York 38
Shenyang 37
Hong Kong 35
Rome 35
Nuremberg 33
Pune 32
Dong Ket 30
Tianjin 28
Washington 28
Hebei 27
Seattle 27
Jiaxing 25
Kunming 24
Woodbridge 24
Dallas 21
Milan 21
Changsha 20
Hangzhou 20
São Paulo 20
Turku 20
Brussels 17
Grevenbroich 16
Norwalk 16
Jinan 14
Toronto 14
Changchun 13
Espoo 13
Frankfurt am Main 13
Augusta 12
Brooklyn 12
Moscow 12
Vienna 12
Brno 11
San Francisco 11
London 10
Falls Church 9
Guangzhou 8
Lanzhou 8
Lappeenranta 8
Orange 8
Rio de Janeiro 8
San Mateo 8
San Vito Chietino 8
Tappahannock 8
Chicago 7
Ningbo 7
Edinburgh 6
Houston 6
Lille 6
Salvador 6
Ascoli Piceno 5
Bari 5
Boston 5
Curitiba 5
Düsseldorf 5
Hefei 5
Mexico City 5
Montreal 5
Olomouc 5
Porto Alegre 5
Shanghai 5
Taipei 5
Albenga 4
Andover 4
Aquila 4
Atlanta 4
Auburn Hills 4
Baku 4
Belo Horizonte 4
Brasília 4
Chennai 4
Hyderabad 4
Leawood 4
Montesilvano 4
Pianella 4
Putignano 4
Totale 6.268
Salva come PNG Salva come JPEG
Nome #
Effect of probiotic supplement on cytokine levels in HIV-infected individuals: A preliminary study 121
Study of immune alterations in patients with Chronic Fatigue Sindrome with different etiologies 119
Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. 114
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C-virus infection and non-alcoholic fatty liver disease. 109
Relevance of plant lectins in human cell biology and immunology 108
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 107
Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. 106
Metabolic modifications in HIV-infected women 104
Cytomegalovirus infection in heart-transplants recipients, in a central region of Italy 103
Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related 102
Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. 100
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 100
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 100
Air and surface measurements of SARS-CoV-2 inside a bus during normal operation 100
The impact of homocysteine, B12, and D vitamins levels on functional neurocognitive performance in HIV-positive subjects 98
STUDIO CLINICO MULTICENTRICO PER LA VALUTAZIONE DELLA MICROALBUMINURIA NEI PAZIENTI CON INFEZIONE DA HIV 97
Dual nucleoside therapy for HIV infection: analysis of results and factors influencing viral response and long term efficacy 96
Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients 96
Interleukin-4 and interferon-gamma production during HIV-1 infection and changes induced by antiretroviral therapy. 94
Long term effect of telmisartan in HIV-positive male patients with high blood pressure 93
Acute urinary retention due to HSV-1: a case report 92
Could S-100b be a marker of the neurologic involvement in HIV-affected patients? 91
Treatment with silibyn- Vitamin E- Phospholipid complex in patients with Hepatitis C infection. 90
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting 90
Inguinal lymphadenopathy due to Bartonella henselae 89
Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy 89
Canakinumab in a subgroup of patients with COVID-19 89
Quality of life, depression and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. 88
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 88
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 88
Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients 87
Cystatin C, adipokines and cardiovascular risk in HIV infected patients. 86
Different strategies of 25OH vitamin D supplementation in HIV+ subjects. 86
IL-1beta induces alkaline phosphatase in human phagocytes 85
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis 84
Is the rate of virological failure to cART continuing to decline in recent calendar years? 84
Cardiac Toxicity Associated with HCV Direct Antiviral Agents 83
Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids 83
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. 82
BNT162b2 mRNA vaccination leads to long-term protection from COVID-19 disease 82
Beneficaial effects of telmisaratan in HIV+ diabetic insulin-dependent patient 81
Normal breathing releases SARS-CoV-2 into the air 81
Proteinuria in an African HIV-infected patient: effects of telmisartan. 80
Effetti del trattamento con vitamina e sulla sintomatologia muscoloscheletrica soggettiva ed oggettiva della sindrome da fatica cronica 80
Antiretroviral therapy management and rationalisation of available resources 80
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 80
Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation 79
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. 78
The proinflammatory interleukin-21 elicits anti-tumor response and mediates autoimmunity 77
Methicillin-resistant staphylococcus epidermidis (MRSE) endocarditis treated with linezolid 77
High dose of erythropoietin in management of interferon/ribavirin induced anemia 76
Hypertension in HIV: Management and Treatment 76
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study 76
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 76
New Therapeutic Options in Mild Moderate COVID-19 Outpatients 75
Increased production of oncostatin-M by lymphomononuclear cells from HIV-1-infected patients with neuroAIDS. 75
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014 75
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? 74
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 74
Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men 74
Short communication: Proangiogenic hematopoietic cells in acute HIV infection 73
Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience 73
Severe HIV-associated hypertriglyceridemia treated with rosuvastatin plus mega-3 fatty acids 72
Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. 72
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 72
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 72
Switch to rilpivirine improves diabetes in an elderly HIV-positive patient 72
Periodontitis and cytokine patterns in HIV positive patients 71
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 71
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 71
Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features 71
Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. 70
Interleukin-31: a new cytokine involved in inflammation of the skin 70
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study 70
Probiotics and anti-inflammatory processes in HIV infection: from Benchside Research to Bedside 70
Assessment of the Vanillin Anti-Inflammatory and Regenerative Potentials in Inflamed Primary Human Gingival Fibroblast 70
Infected atrial mixoma: a rare cause of fever 69
Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV 69
IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances 67
Ruolo delle citochine nella patogenesi delle malattie infettive 67
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 67
Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. 67
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. 67
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. 67
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 67
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 67
Efficacy of canakinumab in mild or severe COVID-19 pneumonia 67
Esophagitis and anticonvulsant hypersensitivity syndrome. 66
Induction with ribavirin in a relapsing patient with chronic HCV hepatitis. 66
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 66
Correlation between neurocognitive disorders and pattern cytokines in HIV+ patients 66
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 65
Inflammatory cytokines and S-100b protein in patients with hepatitis C infection and cryoglobulinemias 64
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 64
Pidotimod and Immunological Activation in Individuals Infected with HIV 64
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 63
Associations between immune depression and cardiovascular events in HIV infection. 63
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 63
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 63
Prevalence of HPV infection among HIV-positive and HIV-negative women in central/eastern Italy: Strategies of prevention 63
Totale 8.064
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.645
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.645
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202026 0 0 0 0 0 0 0 0 0 0 0 26
2020/2021859 122 6 153 18 73 170 33 24 57 82 52 69
2021/2022773 27 24 11 157 46 17 30 57 57 28 80 239
2022/20232.316 208 360 139 241 205 439 131 174 252 27 67 73
2023/20241.157 76 50 84 42 100 326 262 58 9 19 12 119
2024/20252.616 187 528 383 112 60 134 97 183 267 209 336 120
Totale 11.252